Acumen Pharmaceuticals, Inc. (ABOS) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Newton, VA, United States. El CEO actual es James Doherty.
ABOS tiene fecha de IPO 2021-07-01, 61 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $162.34M.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
